1.
Clin Infect Dis
; 73(6): 1107-1109, 2021 09 15.
Article
in English
| MEDLINE
| ID: mdl-33714998
ABSTRACT
We treated 46 patients with multiple recurrent Clostridioides difficile infections (mrCDI) using a tapered-pulsed (T-P) fidaxomicin regimen, the majority of whom failed prior T-P vancomycin treatment. Sustained clinical response rates at 30 and 90 days were 74% (34/46) and 61% (28/46). T-P fidaxomicin shows promise for management of mrCDI.
Subject(s)
Clostridioides difficile , Clostridium Infections , Anti-Bacterial Agents/therapeutic use , Clostridioides , Clostridium Infections/drug therapy , Fidaxomicin , Humans , Recurrence
2.
Clin Infect Dis
; 65(8): 1396-1399, 2017 Oct 15.
Article
in English
| MEDLINE
| ID: mdl-28591789
ABSTRACT
We retrospectively studied vancomycin taper and pulse treatment on 100 consecutive, evaluable patients with recurrent Clostridium difficile infection. Following taper to once-daily vancomycin dosing, 22 of 36 patients (61%) who received every-other-day dosing (QOD) and 50 of 64 (81%) who received QOD followed by every-third-day dosing were cured (P = .03).
